Product
Alirocumab + Cemiplimab
1 clinical trial
1 indication
Indication
NSCLCClinical trial
A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201Status: Recruiting, Estimated PCD: 2027-01-01